[1]郑玉丽,窦灵芝.托拉塞米联合硝普钠静脉滴注对冠心病合并心衰患者心功能及血清卵泡抑素样蛋白1、心血管活性肽Salusin-β的影响[J].陕西医学杂志,2026,(4):524-528.[doi:DOI:10.3969/j.issn.1000-7377.2026.04.016]
　ZHENG Yuli,DOU Lingzhi.The effect of intravenous infusion of torasemide combined with nitroprusside on cardiac function and serum levels of FSTL1 and Salusin-β in patients with coronary heart disease and heart failure[J].,2026,(4):524-528.[doi:DOI:10.3969/j.issn.1000-7377.2026.04.016]
点击复制

托拉塞米联合硝普钠静脉滴注对冠心病合并心衰患者心功能及血清卵泡抑素样蛋白1、心血管活性肽Salusin-β的影响

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
524-528
栏目:
药物与临床
出版日期:
2026-04-05

文章信息/Info

Title:
The effect of intravenous infusion of torasemide combined with nitroprusside on cardiac function and serum levels of FSTL1 and Salusin-β in patients with coronary heart disease and heart failure
作者:
郑玉丽; 窦灵芝
（徐州市中心医院心内科，江苏 徐州 221000）
Author(s):
ZHENG Yuli; DOU Lingzhi
（Department of Cardiology,Xuzhou Central Hospital,Xuzhou 221000,China）
关键词:
托拉塞米; 硝普钠; 冠心病合并心衰; 心功能; 卵泡抑素样蛋白1; Salusin-β蛋白
Keywords:
Torasemide; Sodium nitroprusside; Coronary heart disease combined with heart failure; Heart function; Follicular somatostatin like protein 1; Salusin-β protein
分类号:
R 541.6
DOI:
DOI:10.3969/j.issn.1000-7377.2026.04.016
文献标志码:
A
摘要:
目的：探究对冠心病合并心衰患者采用托拉塞米联合硝普钠进行静脉滴注的治疗方式，对其心功能以及血清中的卵泡抑素样蛋白1（FSTL1）和心血管活性肽Salusin-β 水平产生的影响。方法：选取进行治疗的冠心病合并心衰患者126例，通过随机数字表法分为对照组63例，静脉滴注托拉塞米；联合治疗组63例，在其基础上静脉滴注硝普钠。比较两组治疗一周后的疗效。结果：治疗前两组的血压比较无统计学意义（P＞0.05），治疗后联合治疗组的收缩压、舒张压低于对照组（t=4.691、3.916，均P＜0.001）；且联合治疗组的尿量与血钾均高于对照组（t=11.838、9.933，均P＜0.001）。治疗前两组的左室射血分数、左室舒张末期内径、每搏输出量、6 min步行距离比较差异无统计学意义（均P＞0.05）。治疗后，联合治疗组的左室射血分数、每搏输出量、6 min步行距离高于对照组，左室舒张末期内径低于对照组（均P＜0.001）。治疗前FSTL1、Salusin-β、N末端脑钠肽前体（NTproBNP）、心型脂肪酸结合蛋白（HFABP）表达无统计学意义（均P＞0.05）。治疗后，联合治疗组的FSTL1、Salusin-β、NTproBNP、HFABP均低于对照组（均P＜0.001）。治疗前两组的SF36得分接近（P＞0.05）。治疗后，联合治疗组与对照组的得分均提升（t=9.089，P＜0.001），且联合治疗组的简明健康调查问卷（SF36）分数高于对照组（P＜0.001）。结论：对冠心病合并心衰患者采用托拉塞米联合硝普钠进行静脉滴注的治疗方式，可改善患者的血压、血钾与尿量，对心功能及血清生物标志物水平具有积极影响，并提高生活质量。
Abstract:
Objective:To investigate the effect of torasemide combined with sodium nitroprusside intravenous infusion on cardiac function and serum follistatinlike protein 1 （FSTL1） and cardiovascular active peptide Salusin-β levels in patients with coronary heart disease complicated with heart failure.Methods：A total of 126 patients with coronary heart disease complicated with heart failure were randomly divided into a control group （63 cases） and an intravenous infusion of torasemide.63 cases in the combined group were treated with intravenous sodium nitroprusside on the basis of the combined group.The efficacy of the two groups after one week of treatment was compared.Results:There was no significant difference in blood pressure between the two groups before treatment （P>0.05）.After treatment,the systolic blood pressure and diastolic blood pressure of the combined group were lower than those of the control group （t=4.691,3.916,all P<0.001）.The urine volume and serum potassium of the combined group were higher than those of the control group （t=11.838,9.933,all P<0.001）.There were no significant differences in left ventricular ejection fraction,left ventricular enD-Diastolic diameter,stroke volume,and 6minute walk distance between the two groups before treatment （all P>0.05）.After treatment,the left ventricular ejection fraction,stroke volume and 6minute walk distance of the combined group were higher than those of the control group,and the left ventricular enD-Diastolic diameter was lower than that of the control group （all P<0.001）.There was no significant difference in the expression of FSTL1,Salusin-β,NTproBNP and HFABP before treatment （all P>0.05）.After treatment,the levels of FSTL1,Salusin-β,NTproBNP and HFABP in the combined group were lower than those in the control group （all P<0.001）.The SF36 scores of the two groups were similar before treatment （P>0.05）.After treatment,the scores of the combined group and the control group increased （t=9.089,P<0.001）,and the SF36 score of the combined group was higher than that of the control group （P<0.001）.Conclusion:Torasemide combined with sodium nitroprusside for the treatment of patients with coronary heart disease complicated with heart failure can improve the blood pressure,serum potassium and urine volume,have a positive effect on cardiac function and serum biomarker levels,and improve the quality of life.

参考文献/References:

[1]GHIASI M.Investigating the NF-κB signaling pathway in heart failure：Exploring potential therapeutic approaches[J].Heliyon,2024,10（23）：e40812.
[2]陈佳永,庞延,潘朝锌,等.基于心肌能量代谢探讨中医药防治心力衰竭研究进展[J].陕西中医,2024,45（7）：1002-1005.
[3]蒋沈华,虞坚尔,冯其茂.中药保护线粒体功能在慢性心力衰竭治疗中的应用进展[J].陕西中医,2024,45（7）：1006-1009.
[4]周苗,翁嘉灏,冯其茂,等.常规治疗加用温阳活血方对冠心病合并心衰患者心功能及远期预后的影响观察[J].中国药师,2022,25（7）：1191-1194.
[5]张尤佳,王焕勇,刘宇毅,等.超声心动图与核磁共振成像对冠心病合并心力衰竭患者心功能的评估比较[J].中国循证心血管医学杂志,2024,16（2）：217-220.
[6]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国慢性冠脉综合征患者诊断及管理指南[J].中华心血管病杂志,2024,52（6）：589-614.
[7]中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等.中国心力衰竭诊断和治疗指南2024[J].中华心血管病杂志,2024,52（3）：235-275.
[8]HOLLAND R,RECHEL B,STEPIEN K,et al.Patients’ self-assessed functional status in heart failure by New York Heart Association class：A prognostic predictor of hospitalizations,quality of life and death[J].J Card Fail.2010,16（2）：150-156.
[9]李长青,冯玉宝,苏平.6 min步行试验对于心力衰竭患者的意义[J].心血管康复医学杂志,2018,27（1）：101-103.
[10]龚开政,张振刚,朱宁,等.SF-36在慢性心力衰竭患者中的信度和效度评价[J].中国康复医学杂志,2004,19（3）：182-184.
[11]王京.他汀联合依折麦布在老年冠心病合并血脂异常患者中的疗效及安全性[J].山西医药杂志,2021,50（17）：2532-2534.
[12]OGUNTADE S A,OGAH S O,ADEBIYI A A,et al.Systolic blood pressure,mean arterial pressure and incident mortality in heart failure in a West-African cohort：The blood pressure paradox revisited[J].The Egyptian Journal of Internal Medicine,2024,36（1）：112.
[13]郭晓阳,何岳,邓小秀,等.自拟参附贞芪汤联合利伐沙班治疗慢性心衰的临床疗效研究[J].湖南师范大学学报（医学版）,2023,20（6）：70-72,78.
[14]黄彬,徐秋萍.急性心肌梗死合并急性左心衰患者血清铁调素/铁蛋白比值与临床救治效果的关系[J].中国急救医学,2024,44（3）：200-205.
[15]佟刚,王娉娉,周长宇.注射用硝普钠联合托拉塞米注射液与硝酸甘油注射液联合呋塞米注射液治疗老年慢性心力衰竭临床疗效的对比研究[J].实用心脑肺血管病杂志,2017,25（7）：66-69.
[16]牛川,冯志鹏,赵连玮.芪苈强心胶囊与托拉塞米对慢性充血性心力衰竭病人心室重塑及血清miR-210-3p、miR-423-5p的影响[J].中西医结合心脑血管病杂志,2024,22（16）：3004-3008.
[17]侯绪英,杨红,房修燕,等.厄贝沙坦与硝普钠联合治疗高血压合并心衰对患者心率、血管内皮功能、TNF-α及hs-CRP水平的影响[J].中国循证心血管医学杂志,2023,15（3）：329-332.
[18]高林,王美蓉,陈付成.口服托拉塞米与呋塞米在心力衰竭维持治疗中疗效的比较[J].药学研究,2023,42（9）：730-733.
[19]邓莹,李慧,潘雪瑾,等.生脉注射液联合托拉塞米治疗慢性心力衰竭的临床研究[J].现代药物与临床,2023,38（1）：105-109.
[20]崔继婷,田艳珍,宋凌慧.小剂量螺内酯联合硝普钠对扩张型心肌病致心衰患者血管内皮功能及外周血sST2、sICAM-1的影响[J].微循环学杂志,2023,33（1）：38-42,47.
[21]李丽,蒋芙蓉,赵丽英,等.血清肿瘤坏死因子受体相关因子3和卵泡抑素样蛋白1检测对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值[J].陕西医学杂志,2024,53（9）：1254-1258.
[22]王宇,赵平,贾正培,等.冠状动脉慢血流患者血清Salusin-α、Salusin-β表达水平及预测价值[J].疑难病杂志,2024,23（4）：423-428.
[23]干佳琦,胡梦婷,刘梅.胺碘酮联合厄贝沙坦对高血压合并房颤患者心率变异性及血清N末端B型钠尿肽前体、基质金属蛋白酶-2、白细胞介素-6水平的影响[J].陕西医学杂志,2023,52（10）：1388-1391.
[24]王志新,吴丹,杜洋洋.基于心肌重塑和心功能标志物NT-proBNP、H-FABP水平探讨黄芪注射液治疗慢性心力衰竭的作用[J].广州中医药大学学报,2024,41（7）：1694-1700.
[25]左都坤,李阳,彭滔滔,等.硝普钠控制性降压对猪脑局部血流和氧合的影响[J].陆军军医大学学报,2022,44（17）：1687-1693.

备注/Memo

备注/Memo:
江苏省卫生健康委员会科研项目（2021GRH1065）
更新日期/Last Update: 2026-04-05